Conclusion of non-exclusive rebate agreements pursuant to § 130 a (8) SGB V with the active ingredient glatiramer acetate
Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130 a Abs. 8 SGB V mit dem Wirkstoff Glatiramer acetat
Germany · Düsseldorf · how to bid here →
Your path to submission
- Deadline: 10 November at 10:00 — 34 days left.
- The submission point is stated in the notice (link on the right).
- Offer and evidence in: DEU.
- Collect your evidence — use the eligibility analysis above: it lists the requirements and, for known certificates, how to get them.
Clement What the numbers say about this buyer
- In this sector the buyer awards roughly every month (1821 awards, most recently September 2026) — the next award is due around October 2026 by that rhythm. The last award went to ITF Pharma GmbH.n = 1,821
- 85% of this buyer's awards went to companies that had already won here before (1,822 awards since 2017, spread over 272 companies). That is well above the sector norm (62%) — newcomers have a harder time here than elsewhere.n = 1,822 awards since 2017
- The median procedure drew 3 bids (1,783 procedures with a bid count); 45% ended with a single bidder. Sector: median 2 bids.n = 1,783
- Across 70 procedures with structured selection criteria, this buyer most often required: Quality management (3 of 70), Security of supply required (1 of 70).n = 70
- Not one of the 1,822 awards with a known winner country has gone to a foreign company so far. Sector average: 1%.n = 1,822
From this buyer's documented awards; comparison values from the same sector and country. Not a forecast, not legal advice. As of 04/10/2026.
Foreign bidders
In Germany · Medical equipment & pharma, 265 contracts went to foreign companies over the last 3 years (of 22,200 recorded awards) — mostly from Austria, Netherlands, France.
Submission language: DEU.
Typical field: median 9 (from 2,694 awards).
What the buyer is looking for
GWQ ServicePlus AG intends to conclude non-exclusive discount agreements pursuant to § 130a(8) SGB V on the above-mentioned active substance with the start of the contract on 01.06.2025. All interested companies can join this contract at any time during the term of the contract on the same terms (approval model). The GWQ assumes that this procedure does not fall within the scope of antitrust law due to a lack of a selection decision and therefore the non-discriminatory access of all pharmaceutical companies. The contract documents, the participating health insurance funds and their turnover as well as the dates for the notification of the contract can be viewed and downloaded on the procurement portal of GWQ ServicePlus AG at https://vergabeportal.gwq-serviceplus.de/medicinal products. Until the launch of exclusive contracts, this transitional agreement is open to all market participants…
Show full description
… for accession. Upon receipt of the signed contracts / declaration and evidence on 10.05.2025, a first notification on 01.06.2025 can be realized. The following documents must be submitted: a self-declaration signed by means of an extract from the public part of the ; AMIce database (Annex 3). List of PZNs covered by the contract (Annex 4), self-declaration on the EU Regulation (Annex 5)
What you must prove — eligibility criteria
Contract
Who has won here before
| Company | Awards | Period |
|---|---|---|
| Hexal AG · Holzkirchen | 68 | 2011–2026 |
| Aristo Pharma GmbH · Berlin | 55 | 2011–2026 |
| kohlpharma GmbH · Merzig | 54 | 2016–2023 |
| neuraxpharm Arzneimittel GmbH · Langenfeld | 50 | 2011–2026 |
| ratiopharm GmbH | 49 | 2015–2026 |
How often this buyer tenders this
Who knows the rhythm prepares instead of reacting.